Tango Therapeutics Inc (TNGX)

Name: Tango Therapeutics Inc (TNGX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Tango Therapeutics Inc (TNGX)

Stock Card

$22.35

$-0.49 (-2.15%)

As on 01-Sep-2026 16:02EDT

Market cap

$3,935 Mln

Revenue (TTM)

$54 Mln

P/E Ratio

P/B Ratio

4.2

Div. Yield

0 %

Tango Therapeutics Inc (TNGX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 22.07 High: 23.06

52 Week Range

Low: 6.25 High: 34.39

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.9
Debt to Equity

0
Book Value

$--
EPS

$-0.9
Face value

--
Shares outstanding

168,610,367

5 Years Aggregate

CFO

$-241.32 Mln

EBITDA

$-344.52 Mln

Net Profit

$-334.11 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Tango Therapeutics Inc (TNGX)	152.3	-17.8	1.7	233.1	51.0	13.9	--
BSE Sensex^*	-9.9	-2.3	2.7	-5.1	5.3	5.9	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 01-Sep-2026 | *As on 02-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
Tango Therapeutics Inc (TNGX)	186.7	-68.5	36.6	-33.7
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Tango Therapeutics Inc (TNGX)	22.4	3,935.4	53.8	-123.7	-127.2	-18.1	--	4.2
Arrowhead Pharmaceuticals (ARWR)	82.7	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Cytokinetics Inc (CYTK)	71.4	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	56.9	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	107.7	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	363.8	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	538.7	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	583.2	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	353.4	9,625.4	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	146.5	9,339.4	282.0	82.9	-28.6	11.4	140.1	11.5

Shareholding Pattern

View Details

About Tango Therapeutics Inc (TNGX)

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase... 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts. Read more

President, CEO & Director

Dr. Barbara L. Weber M.D.
President, CEO & Director

Dr. Barbara L. Weber M.D.
Headquarters

Boston, MA
Website

https://www.tangotx.com

FAQs for Tango Therapeutics Inc (TNGX)

What is the current share price of Tango Therapeutics Inc (TNGX) Today?

The share price of Tango Therapeutics Inc (TNGX) is $22.35 (NASDAQ) as of 01-Sep-2026 16:02 EDT. Tango Therapeutics Inc (TNGX) has given a return of 51.01% in the last 3 years.

What is the current PB & PE ratio of Tango Therapeutics Inc (TNGX)?

Since, TTM earnings of Tango Therapeutics Inc (TNGX) is negative, P/E ratio is not available.
The P/B ratio of Tango Therapeutics Inc (TNGX) is 4.16 times as on 28-Aug-2026, a 20 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-10.13	2.97
2024	-2.58	1.68
2023	-9.32	3.75
2022	-5.90	2.56
2021	-16.45	2.78

What is the 52 Week High and Low of Tango Therapeutics Inc (TNGX)?

The 52-week high and low of Tango Therapeutics Inc (TNGX) are Rs 34.39 and Rs 6.25 as of 02-Sep-2026.

What is the market cap of Tango Therapeutics Inc (TNGX)?

Tango Therapeutics Inc (TNGX) has a market capitalisation of $ 3,935 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Tango Therapeutics Inc (TNGX)?

Before investing in Tango Therapeutics Inc (TNGX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.